These metabolic improvements are accompanied by enhanced insulin sensitivity, supporting their potential for the simultaneous treatment of glycemic and lipid abnormalities in patients with type 2 diabetes mellitus (T2DM) [145,146,147,148]. This evidence concerns the gene INS and type 2 diabetes mellitus.